HSA
EBS icon

Hussman Strategic Advisors’s Emergent Biosolutions EBS Stock Holding History

Hussman Strategic Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-105,000
Closed -$670K – 298
2025
Q2 		$670K Buy
105,000
+84,000
+400% +$481K 0.15% 173
2025
Q1 		$102K Hold
21,000
– – 0.02% 208
2024
Q4 		$201K Buy
+21,000
New +$193K 0.06% 210
2019
Q2 		– Sell
-10,000
Closed -$505K – 200
2019
Q1 		$505K Hold
10,000
– – 0.12% 184
2018
Q4 		$593K Sell
10,000
-15,000
-60% -$967K 0.14% 185
2018
Q3 		$1.65M Buy
+25,000
New +$1.46M 0.48% 94

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Hussman Strategic Advisors's EBS Position: Q3 2025 in Review

Hussman Strategic Advisors sold out of Emergent Biosolutions (EBS) in Q3 2025, closing a stake of 105,000 shares — an estimated $670K sold.

Hussman Strategic Advisors first reported a position in EBS in Q3 2018 and held it in 6 quarters. The position peaked at $1.65M in Q3 2018. 169 funds tracked by Wall St. Rank hold EBS as of Q3 2025.

  • Hussman Strategic Advisors reported no remaining Emergent Biosolutions position as of Q3 2025 after selling out during the quarter.
  • Hussman Strategic Advisors sold 105,000 Emergent Biosolutions shares in Q3 2025, an estimated $670K.
  • Hussman Strategic Advisors first reported a position in Emergent Biosolutions in Q3 2018 and held it in 6 quarters.
  • Hussman Strategic Advisors's Emergent Biosolutions position peaked at $1.65M in Q3 2018.
  • 169 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2025.

Based on Hussman Strategic Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.